Media coverage about Kamada (NASDAQ:KMDA) has been trending somewhat negative on Friday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kamada earned a coverage optimism score of -0.10 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.8925020330804 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
KMDA has been the subject of a number of analyst reports. Zacks Investment Research upgraded Kamada from a “sell” rating to a “hold” rating in a research note on Tuesday, August 15th. ValuEngine downgraded Kamada from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Jefferies Group LLC reiterated a “buy” rating and set a $7.00 price target on shares of Kamada in a research note on Thursday. Finally, TheStreet downgraded Kamada from a “c-” rating to a “d+” rating in a research note on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating and two have issued a buy rating to the company’s stock. Kamada presently has an average rating of “Hold” and a consensus price target of $8.50.
Kamada (NASDAQ KMDA) traded down 1.058% during trading on Friday, reaching $4.675. The company’s stock had a trading volume of 33,020 shares. The company has a 50-day moving average of $4.65 and a 200 day moving average of $5.94. Kamada has a one year low of $3.75 and a one year high of $8.61. The firm’s market cap is $174.85 million.
Kamada (NASDAQ:KMDA) last posted its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported $0.13 EPS for the quarter, beating the Zacks’ consensus estimate of $0.12 by $0.01. Kamada had a negative net margin of 2.24% and a negative return on equity of 2.94%. The firm had revenue of $32.55 million for the quarter, compared to analysts’ expectations of $33.30 million. During the same quarter in the prior year, the company posted ($0.04) earnings per share. The business’s revenue for the quarter was up 70.7% on a year-over-year basis. Analysts expect that Kamada will post $0.09 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.truebluetribune.com/2017/10/13/somewhat-negative-news-coverage-somewhat-unlikely-to-affect-kamada-kmda-share-price.html.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.